Arlocabtagene Autoleucel

Arlocabtagene Autoleucel (CC-95266, BMS-986393) is a CAR-T cell therapy developed by Juno Therapeutics, a Bristol-Myers Squibb. Its target is GPRC5D (the sponsor names GPRC5D). The sponsor states: Arlocabtagene autoleucel (BMS-986393, CC-95266) is a GPRC5D-directed CAR T cell therapy, engineered to target GPRC5D-expressing myeloma cells, given as an infusion to heavily pretreated relapsed/refractory multiple myeloma patients. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06615479 (A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)), in multiple myeloma. The largest, NCT06615479, plans to enrol 440 participants with primary completion expected 2027-12-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.